Early Detection and Treatment of Preeclampsia After Delivery in Nepal
Tests a care bundle for postpartum preeclampsia, using blood tests to find higher-risk women.
Plain-language title generated from the registry record
Registry title: Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
Key facts
- Where
- Dhulikhel, NepalSee the site
Where in Nepal
- Dhulikhel HospitalDhulikhel, NepalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07185204
- Record updated
- 20 July 2026
- Original description
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.Read full original descriptionShow less
Postpartum Preeclampsia Early Detection and Treatment: Using Biomarkers to Implement Risk-stratified Intervention (Nepal Pilot Randomized Controlled Trial)
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Inclusion: Pregnant patients ≥ 36 weeks gestation without major fetal anomalies; Age ≥ 18 years; Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital; At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF; 1 or more high risk factors:; History of preeclampsia; Type 1 or 2 diabetes; Multifetal gestation?; Renal disease; Autoimmune disease; 2 or more moderate risk factors:; Nulliparity; BMI > 30; First-degree relative with a history of preeclampsia; African American race; Low socioeconomic status; Age > 35 years; History of low birthweight or small for gestational age; Previous adverse pregnancy outcome; Interpregnancy interval > 10 years.
Exclusion: Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria); Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines; Chronic hypertension, according to ACOG guidelines; Known allergy or contraindication to nifedipine; Inability or unwillingness to provide informed consent.